A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Latest Information Update: 23 Oct 2023
At a glance
- Drugs Milademetan (Primary)
- Indications Adenocarcinoma; Adrenocortical carcinoma; Advanced breast cancer; Biliary cancer; Bladder cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Lung cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Acronyms MANTRA-2
- Sponsors Rain Oncology
- 16 Oct 2023 Status changed from suspended to discontinued as per sponsor decision.
- 10 Aug 2023 According to a Rain Therapeutics media release, submitted abstracts to upcoming medical conferences; anticipate presentations in 4Q 2023.
- 10 Aug 2023 According to a Rain Oncology media release, suspended enrollment in May 2023 and trial will be discontinued in 4Q 2023.